189 related articles for article (PubMed ID: 26391142)
21. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
22. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
23. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
Basheer L; Schultz K; Fichman M; Kerem Z
PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
[TBL] [Abstract][Full Text] [Related]
24. Influence of
Zhang X; Liu C; Zhou S; Xie R; He X; Wang Z; Yi H; Shu Y; Wang Z; Hu K; Ma L; Cui Y; Zhao X; Xiang J
Pharmacogenomics; 2021 Mar; 22(4):213-223. PubMed ID: 33586456
[No Abstract] [Full Text] [Related]
25. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract][Full Text] [Related]
26. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
27. Lotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity.
Ye LH; Kong LT; Yan MZ; Cao FR; Wang LS; Liao YH; Pan RL; Chang Q
J Ethnopharmacol; 2016 Dec; 194():913-917. PubMed ID: 27771456
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro.
Wang L; Wang Z; Xia MM; Wang YY; Wang HY; Hu GX
Can J Physiol Pharmacol; 2014 Nov; 92(11):961-4. PubMed ID: 25365188
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
30. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
Koller D; Belmonte C; Lubomirov R; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Carcas A; Wojnicz A; Abad-Santos F
J Psychopharmacol; 2018 Nov; 32(11):1212-1222. PubMed ID: 30251598
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics.
Sawant K; Pandey A; Patel S
Mater Sci Eng C Mater Biol Appl; 2016 Sep; 66():230-243. PubMed ID: 27207059
[TBL] [Abstract][Full Text] [Related]
32. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
Wang R; Zhang H; Wang Y; Yu X; Yuan Y
J Ethnopharmacol; 2016 Mar; 180():87-96. PubMed ID: 26806573
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats.
Shi Y; Lu Z; Song W; Wang Y; Zhou Q; Geng P; Zhou Y; Wang S; Han A
Drug Des Devel Ther; 2024; 18():931-939. PubMed ID: 38560524
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 inhibitory potential and RP-HPLC standardization of trikatu--a Rasayana from Indian Ayurveda.
Harwansh RK; Mukherjee K; Bhadra S; Kar A; Bahadur S; Mitra A; Mukherjee PK
J Ethnopharmacol; 2014 May; 153(3):674-81. PubMed ID: 24690772
[TBL] [Abstract][Full Text] [Related]
35. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
36. Baicalein inhibits the pharmacokinetics of simvastatin in rats
Meng M; Li X; Zhang X; Sun B
Pharm Biol; 2021 Dec; 59(1):880-883. PubMed ID: 34214011
[TBL] [Abstract][Full Text] [Related]
37. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine.
Wang RW; Liu L; Cheng H
Drug Metab Dispos; 1996 Jul; 24(7):786-91. PubMed ID: 8818577
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
39. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
40. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
